RCCRounds: Incorporating Novel Therapeutics for Improved Patient Care in Renal Cell
Carcinoma
A CME-Certified Activity
|
Evaluation and First-Line
Treatment of the Patient
With Clear Cell mRCC
Click here
to begin activity
Module 1
|
The Second-Line Conundrum:
Strategies for Handling
Disease Progression
Click here
to begin activity
Module 2
|
Science on the Move:
Clinical Trials to Watch
Click here
to begin activity
Module 3
|
Chair
Robert J. Motzer, MD
Medical Oncologist
Genitourinary Division
Memorial Sloan-Kettering Cancer Center
New York, New York
Faculty
Robert A. Figlin, MD
Chair, Medical Oncology and Experimental Therapeutics
Acting Cancer Center Director
City of Hope
Duarte, California
Effective Dates
August 2008 through August 31, 2009
Estimated Time to Complete Activity
45 minutes per module (135 minutes total)
Program Overview
Improving patient care by incorporating evidence-based research on targeted therapies
into the management of patients with metastatic renal cell carcinoma (RCC) provides
a challenge for the busy oncologist. Continuing education activities designed to
translate clinical trial data into therapeutic strategies can provide much needed
guidance.
The role of approved and emerging agents for the management of RCC continues to
evolve. Approval of three targeted therapies for use as single agents represents
significant progress in improved patient care. Emerging data on the sequential use
of single agent therapy and potential identification of indicators for responsiveness
to therapy continue to challenge the oncologist’s comfort with identifying patients
most likely to respond. In addition, it has become apparent that combining targeted
therapies which inhibit the same or distinct pathways, as well as using targeted
therapies to enhance cytokine therapy, shows great promise. Finally, there are opportunities
for the oncologist to improve patient outcomes by referral to numerous ongoing clinical
trials.
Method of Participation
Follow along with the slides and audio, complete the CME Activity Evaluation and
Request for Credit Form online, and receive your statement of credit immediately.
This activity is provided free of charge to participants.
Intended Audience
Community oncologists treating patients with advanced renal cell carcinoma
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Veritas Institute for Medical Education, Inc. designates each educational activity
for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians
should only claim credit commensurate with the extent of their participation in
the activity.
Sponsorship and Support
Sponsored by Veritas Institute for Medical Education, Inc.
Supported by an educational grant from Novartis Oncology and Pfizer Inc.
Financial Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME providers
are required to disclose to the activity audience the relevant financial relationships
of the planners, teachers, and authors involved in the development of CME content.
An individual has a relevant financial relationship if he or she has a financial
relationship in any amount occurring in the last 12 months with a commercial interest
whose products or services are discussed in the CME activity content over which
the individual has control. Disclosures are as follows:
Robert A. Figlin, MD: Keryx Biopharmaceuticals, Pfizer Inc, Wyeth (consultant);
Amgen, Pfizer Inc, Wyeth (research support).
Robert J. Motzer, MD: Genentech, Novartis, Pfizer Inc, Wyeth (grant/research
support); Bayer/Onyx Pharmaceuticals (speakers bureau).
The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.
The independent content reviewer has nothing to disclose.
Unlabeled Use Disclosure Statement
Participants are advised that this CME activity will contain references to unlabeled/unapproved/investigational
uses of drugs to treat renal cell carcinoma.
Disclaimer
The opinions expressed in this activity are those of the faculty and do not necessarily
reflect those of Veritas Institute for Medical Education, Inc., Novartis Oncology,
or Pfizer Inc. Please consult the appropriate package insert for full prescribing
information on all drug therapies discussed.
Copyright © 2008 Veritas Institute for Medical Education, Inc.
Terms
and
Privacy Policy. All rights reserved.
Module 1 Learning Objectives
- You will be able to assess the role and efficacy of approved first-line therapies in the treatment of RCC with clear cell histology.
- You will be able to describe prognostic variables in patients with RCC and to correlate patient outcomes based on stratified risk groups.
Module 2 Learning Objectives
- You will be able to assess the role and efficacy of second-line therapies in the treatment of RCC with clear cell histology.
- You will be able to describe the clinical parameters that influence therapeutic selection for managing patients with disease progression.
Module 3 Learning Objectives
- You will be better able to assess the role of emerging therapeutic agents for the treatment of metastatic renal cell carcinoma.
- You will be able to appraise the emerging clinical data on biological therapies for the treatment of RCC in order to be better able to refer your patients to appropriate clinical trials.
|
Evaluation and First-Line
Treatment of the Patient
With Clear Cell mRCC
Click here
to begin activity
Module 1
|
The Second-Line Conundrum:
Strategies for Handling
Disease Progression
Click here
to begin activity
Module 2
|
Science on the Move:
Clinical Trials to Watch
Click here
to begin activity
Module 3
|
|
|